AstraZeneca PLC $AZN is Martin Investment Management LLC’s 5th Largest Position

Martin Investment Management LLC raised its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 3.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 322,034 shares of the company’s stock after acquiring an additional 11,035 shares during the quarter. AstraZeneca comprises approximately 5.8% of Martin Investment Management LLC’s portfolio, making the stock its 5th biggest holding. Martin Investment Management LLC’s holdings in AstraZeneca were worth $22,504,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in AZN. Lindbrook Capital LLC raised its stake in shares of AstraZeneca by 1.9% during the 1st quarter. Lindbrook Capital LLC now owns 7,574 shares of the company’s stock valued at $557,000 after purchasing an additional 141 shares during the period. Sage Mountain Advisors LLC grew its holdings in AstraZeneca by 3.4% during the 1st quarter. Sage Mountain Advisors LLC now owns 4,478 shares of the company’s stock valued at $329,000 after buying an additional 147 shares in the last quarter. Pekin Hardy Strauss Inc. grew its holdings in AstraZeneca by 4.2% during the 2nd quarter. Pekin Hardy Strauss Inc. now owns 3,650 shares of the company’s stock valued at $255,000 after buying an additional 148 shares in the last quarter. Richardson Financial Services Inc. increased its position in shares of AstraZeneca by 59.8% during the second quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after buying an additional 149 shares during the period. Finally, Evergreen Capital Management LLC lifted its holdings in shares of AstraZeneca by 0.7% in the first quarter. Evergreen Capital Management LLC now owns 23,709 shares of the company’s stock worth $1,743,000 after buying an additional 155 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Thursday, October 16th. Jefferies Financial Group started coverage on shares of AstraZeneca in a report on Monday, October 27th. They issued a “buy” rating for the company. Finally, Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.

AstraZeneca Stock Up 1.0%

AZN stock opened at $84.58 on Friday. The company’s 50 day moving average is $81.41 and its 200 day moving average is $75.55. The stock has a market cap of $262.32 billion, a price-to-earnings ratio of 31.80, a price-to-earnings-growth ratio of 1.52 and a beta of 0.34. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $86.57.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.05. The business had revenue of $15.19 billion during the quarter, compared to analyst estimates of $14.75 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. AstraZeneca’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same period in the previous year, the business posted $2.08 earnings per share. Sell-side analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.